Depo-Provera Brain Tumor Lawsuit: What the 2026 Settlement Means for You

Thousands of women who received the Depo-Provera birth control injection are now part of one of the fastest-moving pharmaceutical litigations in the country. The depo-provera meningioma lawsuit centers on a single allegation: that Pfizer knew, or should have known, that long-term use of this injectable contraceptive was tied to a heightened risk of meningioma a tumor that grows on the tissue lining the brain and spinal cord and failed to warn patients or doctors. As of August 2026, more than 6,200 federal cases are consolidated in a multidistrict litigation (MDL), and both sides have signed a master settlement agreement that could resolve a large share of the pending claims. This guide breaks down where the litigation stands today, what the depo-provera settlement actually covers, how the depo provera meningioma Canada cases differ from the U.S. MDL, and what women need to do if they believe they have a claim.

What Is the Depo-Provera Meningioma Lawsuit?

Depo-Provera (medroxyprogesterone acetate) is an injectable contraceptive given roughly every three months. It has been on the market for decades, but growing scientific evidence has connected prolonged, high-dose use of the drug to intracranial and spinal meningiomas typically slow-growing but sometimes debilitating tumors that can require invasive brain or spinal surgery. The depo-provera injection lawsuits allege that Pfizer failed to update U.S. warning labels despite research linking the hormone to tumor growth, and that women were denied the chance to weigh that risk against other birth control options.

The first depo-provera brain tumor lawsuit was filed in October 2024 by a woman who had used the injection between 2005 and 2021. Since then, filings have accelerated sharply. In February 2025, the U.S. Judicial Panel on Multidistrict Litigation transferred the growing number of federal cases to the Northern District of Florida for coordinated pretrial proceedings under Judge M. Casey Rodgers, allowing plaintiffs to share scientific evidence, expert testimony, and company records while each woman’s individual claim moves forward separately.

The Science Behind the Depo Provera Meningioma Connection

A widely cited case-control study published in The BMJ in March 2024 found that women who used high-dose injectable medroxyprogesterone acetate for more than a year faced roughly a five- to five-and-a-half-fold increase in the risk of developing a meningioma serious enough to require surgery, compared with non-users. Meningiomas are hormone-sensitive, meaning their growth can be fueled by progestin exposure the same mechanism plaintiffs’ attorneys argue Pfizer should have flagged decades earlier.

Notably, regulators in Canada and the European Union added meningioma warnings to Depo-Provera labeling years before the U.S. label was updated. The FDA did not add an equivalent meningioma warning in the United States until December 2025 a gap that plaintiffs argue left American patients uninformed for years after the risk was already known abroad.

Depo-Provera Lawsuit 2026 Timeline

• October 2024 — First depo-provera meningioma lawsuit filed in California
• February 2025 — JPML consolidates federal cases into an MDL in the Northern District of Florida
• December 2025 — FDA adds a meningioma warning to the Depo-Provera U.S. label
• April 2026 — Pending MDL filings reach roughly 3,490 cases
• June 2026 — Pfizer and plaintiffs’ leadership announce an agreement in principle on a global settlement framework
• July 21, 2026 — Master Settlement Agreement formally signed
• August 2026 — Pending federal cases exceed 6,200; settlement registration process finalized
• November 2026 (expected) — Settlement registration closes
• Q1 2027 (expected) — Claims review begins and first payments are issued

Depo-Provera Settlement: What Was Actually Agreed?

On July 21, 2026, Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement covering a substantial share of the federal MDL Pfizer has estimated the framework could resolve roughly 80% of pending cases. The court has since paused several litigation deadlines, including the previously scheduled bellwether trial, to allow the settlement process to move forward. Cases that fall outside the framework, or where a plaintiff opts out, are expected to continue toward individual trial proceedings, including a hearing scheduled for September 2026.

Depo Provera Meningioma Settlement Amounts: What to Expect

Because the Depo-Provera meningioma settlement program has not finished processing claims, no official payout figures have been released. Attorneys who track comparable pharmaceutical injury litigation offer these figures only as rough estimates, based on the severity of the tumor, whether surgery or radiation was required, lost income, and the strength of the medical causation evidence:

• Smaller, treatable meningioma with limited lasting impact: roughly $100,000 – $500,000
• Larger tumor requiring surgery or radiation with ongoing effects: roughly $500,000 – $1 million+
• Severe, permanently disabling cases with strong evidence of negligence: roughly $1 million – $5 million or more

For comparison, meningioma-related injury settlements outside this litigation have averaged more than $800,000, with some jury verdicts exceeding $3 million, according to data compiled from the National Library of Medicine. These numbers are illustrative only every depo-provera meningioma settlement will be evaluated on its own facts.

Depo Provera Meningioma Canada: How the Canadian Cases Differ

Canadian women pursuing a depo provera meningioma Canada claim are working through a separate legal system entirely. Firms including Siskinds LLP, Consumer Law Group, and Gluckstein Lawyers are investigating or actively building a Canada-wide class action against Pfizer Canada, alleging the company was negligent in its design, testing, and labeling of Depo-Provera and failed to warn Canadian patients and physicians about meningioma risk. As of mid-2026, no class action has yet been certified in Canada the case remains in the investigation and intake phase, with law firms gathering plaintiffs ahead of a formal certification motion.

This isn’t Canada’s first Depo-Provera litigation. In 2021, Pfizer settled a Canadian class action over Depo-Provera’s link to bone mineral density loss for close to $2 million. That earlier case shows Canadian courts have already held Pfizer accountable for inadequate warnings tied to this same drug a precedent Canadian plaintiffs’ lawyers are pointing to as they build the meningioma case.

Is There a Depo-Provera Class Action Lawsuit?

This is one of the most searched questions in this litigation, and the answer is nuanced. In the United States, the depo-provera class action lawsuit label is technically inaccurate the federal cases are consolidated as an MDL, not a certified class action. That distinction matters: in an MDL, every plaintiff files and controls her own individual lawsuit, and any settlement or verdict is calculated on a case-by-case basis rather than split evenly across a class. Cases are grouped only to streamline shared evidence like scientific studies, corporate documents, and expert witnesses.
In Canada, by contrast, the Depo-Provera meningioma case is structured as an actual proposed class action, though it has not yet reached certification. So a woman searching for a depo-provera class action lawsuit gets a different answer depending on which country she’s in individual MDL claims in the U.S., and a proposed (not yet certified) class proceeding in Canada.

Who Qualifies for a Depo-Provera Meningioma Lawsuit?

Eligibility generally depends on documented use of the drug and a confirmed diagnosis. Typical qualifying criteria include:
• Received Depo-Provera, Depo-SubQ Provera, or an approved generic injection on at least two occasions
• Later received an image-confirmed diagnosis (MRI or CT) of a cranial or spinal meningioma
• Used the injection for an extended period, generally more than one year, when risk increases most significantly
• Can produce pharmacy, prescription, or medical records connecting the injections to the diagnosis
• Filed within your state’s statute of limitations, which typically ranges from one to six years depending on where you live
If a loved one passed away after a meningioma diagnosis linked to Depo-Provera use, her estate may also be eligible to pursue a wrongful death or survival claim, depending on state law.

How to File a Depo-Provera Meningioma Claim

1. Gather medical records confirming your meningioma diagnosis, including imaging reports and treatment history.
2. Collect pharmacy or prescription records documenting your Depo-Provera injection history and dates of use.
3. Consult a product liability attorney experienced in pharmaceutical MDL litigation to evaluate your eligibility.
4. File your individual complaint in the federal MDL (or connect with Canadian counsel if you were treated in Canada).
5. Track settlement registration deadlines closely missing a filing window can permanently affect your eligibility.

Symptoms That May Signal a Meningioma

Meningiomas often grow slowly and can go unnoticed for years. Women who have used Depo-Provera long-term are advised to watch for:
• Persistent or worsening headaches
• Vision changes, including blurred or double vision
• Hearing loss or ringing in the ears
• Balance problems or dizziness
• Memory issues or unexplained seizures
These symptoms don’t confirm a meningioma on their own, but anyone experiencing them after using Depo-Provera should seek prompt medical evaluation and keep detailed records for any potential claim.

Frequently Asked Questions

Is there an active Depo-Provera meningioma class action lawsuit in the U.S.?
No. U.S. cases are consolidated as a multidistrict litigation (MDL) in the Northern District of Florida, not a certified class action. Each woman files and controls her own individual lawsuit, though shared evidence is handled together.

What is the status of the Depo-Provera settlement as of 2026?
Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement on July 21, 2026, covering an estimated 80% of pending federal cases. Registration is expected to be completed by November 2026, with claims review and first payments projected for the first quarter of 2027.

How much is the average Depo-Provera meningioma settlement amount?
No official figures have been released. Legal estimates, based on comparable meningioma litigation, range from roughly $100,000 for milder, treatable cases to $1 million–$5 million or more for severe, permanently disabling diagnoses. Actual settlement amounts depend on individual medical evidence.

Is the Depo-Provera meningioma lawsuit different in Canada?
Yes. The depo provera meningioma Canada case is being pursued as a proposed nationwide class action, currently in the investigation and pre-certification stage, separate from the U.S. federal MDL. No Canadian class action has been certified yet as of 2026.

Who is eligible to file a Depo-Provera injection lawsuit?
Women who received at least two Depo-Provera (or generic medroxyprogesterone acetate) injections and were later diagnosed with an image-confirmed cranial or spinal meningioma may qualify, provided their claim falls within their state’s statute of limitations.

Does filing now protect me if the settlement changes?
Not automatically. Legal sources caution that registering interest in the settlement does not pause the statute of limitations on an unfiled claim, and a later filing is not guaranteed to qualify. Speaking with an attorney promptly is important.

Will there be a Depo-Provera bellwether trial?
A bellwether trial was originally scheduled for December 2026 to test liability and causation issues before a jury. Following the June 2026 settlement announcement, the court paused several trial deadlines while the settlement framework is finalized.

What did Pfizer settle for in the earlier Depo-Provera lawsuit?
Separate from the meningioma litigation, Pfizer previously paid more than $2 million to resolve claims (including a 2021 Canadian class action) alleging Depo-Provera caused bone mineral density loss without adequate warning.

Last Updated on: September 2, 2026